SGLT2 inhibitor dapagliflozin enhances skeletal muscle fatty acid uptake in subjects with type 2 diabetes: a positron emission tomography study

被引：0
|
作者：
Latva-Rasku, A. [1 ]
Tuisku, J. [1 ]
Bhowmik, A. [1 ]
Keskinen, H. [1 ]
Rebelos, E. [1 ]
Laurila, S. [1 ]
Koffert, J. [1 ]
Nummenmaa, L. [1 ]
Heurling, K. [2 ]
Oscarsson, J. [3 ]
Turku, P. Nuutila [1 ]
机构：
[1] Univ Turku, Turku PET Ctr, Turku, Finland
[2] Antaros Med, Molndal, Sweden
[3] AstraZeneca AB, Molndal, Sweden
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
133
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [41] Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects
    Komoroski, B.
    Vachharajani, N.
    Boulton, D.
    Kornhauser, D.
    Geraldes, M.
    Li, L.
    Pfister, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (05) : 520 - 526
  • [42] Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus
    Komoroski, B.
    Vachharajani, N.
    Feng, Y.
    Li, L.
    Kornhauser, D.
    Pfister, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (05) : 513 - 519
  • [43] The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus
    Sugiyama, Seigo
    Jinnouchi, Hideaki
    Kurinami, Noboru
    Hieshima, Kunio
    Yoshida, Akira
    Jinnouchi, Katsunori
    Nishimura, Hiroyuki
    Suzuki, Tomoko
    Miyamoto, Fumio
    Kajiwara, Keizo
    Jinnouchi, Tomio
    INTERNAL MEDICINE, 2018, 57 (15) : 2147 - 2156
  • [44] DAPAGLIFLOZIN, A SELECTIVE SGLT2 INHIBITOR, IMPROVED GLYCEMIC CONTROL OVER 2 WEEKS IN PATIENTS WITH TYPE 1 DIABETES MELLITUS
    Kasichayanula, S.
    Griffen, S. C.
    Chalamandaris, A.
    LaCreta, F.
    Boulton, D. W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S19 - S20
  • [45] A Dose Ranging Study with the SGLT2 inhibitor AVE2268 in Type 2 Diabetes
    Mezzetti, A.
    Ellis, G.
    Souhami, E.
    Derwahl, K. M.
    PROCEEDINGS OF THE 13TH INTERNATIONAL CONGRESS OF ENDOCRINOLOGY, 2008, : 497 - +
  • [46] A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
    Jung, Chang Hee
    Jang, Jung Eun
    Park, Joong-Yeol
    DIABETES & METABOLISM JOURNAL, 2014, 38 (04) : 261 - 273
  • [47] TOFOGLIFLOZIN: A HIGHLY SELECTIVE SGLT2 INHIBITOR FOR THE TREATMENT OF TYPE 2 DIABETES
    Rosenwasser, R. F.
    Rosenwasser, J. N.
    Sutton, D.
    Choksi, R.
    Epstein, B.
    DRUGS OF TODAY, 2014, 50 (11) : 739 - 745
  • [48] The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation
    Cho, Yongin
    Shin, Sung-Hee
    Park, Min-Ae
    Suh, Young Ju
    Park, Sojeong
    Jang, Ji-Hun
    Kim, Dae-Young
    Kim, So Hun
    PLOS ONE, 2025, 20 (02):
  • [49] A Prospective Observational Study to Assess the Efficacy of a SGLT2 Inhibitor (Dapagliflozin) in Kidney Allograft Recipients with Diabetes Mellitus
    Naskar, Avishek
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024, 35 (10):
  • [50] Efficacy and safety of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: A meta-analysis of randomized controlled trials
    Huang, Yuxin
    Jiang, Zeju
    Wei, Yiping
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 21 (04)
12345